NGR‐hTNF and Doxorubicin as Second‐Line Treatment of Patients with Small Cell Lung Cancer

LESSONS LEARNED. NGR‐hTNF was safely combined with doxorubicin, showing a promising antitumor activity in unselected patients with relapsed small cell lung cancer. Similar antitumor activity was observed in platinum‐sensitive and platinum‐resistant patient cohorts. BACKGROUND. Relapsed small cell lu...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncologist
Main Authors: Gregorc, Vanesa, Cavina, Raffaele, Novello, Sivia, Grossi, Francesco, Lazzari, Chiara, Capelletto, Enrica, Genova, Carlo, Salini, Giulia, Lambiase, Antonio, Santoro, Armando
Formato: Artigo
Idioma:Inglês
Publicado em: AlphaMed Press 2018
Assuntos:
Clinical Trial Results
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6263121/
https://ncbi.nlm.nih.gov/pubmed/30076277
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2018-0292
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados